key: cord-0744091-vj0r5c1l
authors: Laury, Jessica; Hiebert, Lindsey; Ward, John W.
title: Impact of COVID‐19 Response on Hepatitis Prevention Care and Treatment: Results From Global Survey of Providers and Program Managers
date: 2021-02-01
journal: Clin Liver Dis (Hoboken)
DOI: 10.1002/cld.1088
sha: 3178228bd307ef77ade6eeb43195b0a510134d5d
doc_id: 744091
cord_uid: vj0r5c1l

Watch a video presentation of this article

The survey addressed four areas: (1) HBV and HCV services delivered before the emergence of COVID-19, during the month most heavily impacted by the pandemic and the month of survey completion; (2) the mitigation strategies deployed to safely deliver hepatitis testing and treatment services; (3) respondents' participation in the COVID-19 response; and (4) perceived benefits to hepatitis systems from the response to COVID-19. Program managers were asked about supply chain disruptions and training activities. These questions were added during the second iteration of the survey and were not administered to the first 32 respondents.

The survey respondents included 103 clinicians and program managers from 44 countries. † Respondents were from six World Health Organization (WHO) regions, including the Americas (55 [53%]), the African Region (28 [27%]), and the European Region (15 [15%]). Most respondents, 86%, were physicians or nurses providing care in academic health centers (31%) or public hospitals (41%).

All respondents reported February, March, April, or May as the month of highest COVID-19 impact. In heavily impacted months, 60 of 92 (65%) respondents reported deferring >50% of in-person clinic visits (Fig. 1 ). Most respondents (64%) reported improvements in delivery of in-person hepatitis care in the current month. However, 80% reported the volume of in-person care remained lower than pre-COVID levels. The most common challenge hindering a return to pre-COVID-19 service levels was patients' anxiety and fear (71%, 39/55) (Fig. 2) .

To mitigate SARS-CoV-2 transmission risks, almost all respondents reported wearing masks (89%, 85/96), and 34% reported use of other personal protective equipment, that is, gowns and gloves. In addition, 51% reported monitoring patients for COVID-19 symptoms/signs, including fever, and 59% required patients to wear masks ( Table 1 , mitigation strategies for distance-based care). Providers used direct (82%) and public communications 

Of respondents treating patients for HCV or HBV infection, 88% (59/67) and 80% (49/61) reported some level of disruption, and 39% (26/67) and 21% (13/61) reported a >50% decline in treatment volumes, respectively. Similarly, 28% (23/82) and 27% (19/70) of respondents reported >50% declines in HCV and HBV screening, respectively (Fig. 3) . About 79% (19/24) of respondents implementing opioid substitution therapy reported disruptions, including 21% (5/24) with >50% decline in patients receiving opioid substitution therapy. Program managers also reported supply chain disruptions ( Table 2) .

A variety of mitigation strategies were used to meet patients' needs and limit the risk for SARS-CoV-2 transmission. During the month when care was most affected by the COVID-19 pandemic, the majority of respondents (55/90) increased pill counts per prescription, 77% deferred imaging, 63% deferred laboratory work, and 30% (2/94) of respondents reported delivery of >75% of patient care via telemedicine (audio and/ or video) ( Table 1 , mitigation strategies for distancebased care); by the month of survey completion, only 10% (9/87) reported the use of telemedicine to this extent (Table 1 , mitigation strategies for distance-based care). 

Respondents identified several aspects of the COVID-19 response potentially improving hepatitis care. Increases in the capacity of laboratory testing (47%, 43/91) and improved health worker training (48%, 44/91) were the most commonly identified potential benefits (Fig. 4) .

Risk mitigation strategies varied by region (Table 1 , mitigation strategies for distance-based care). Respondents in the Americas were mostly likely to report continued use of telemedicine strategies, while 95% (19/20) of African respondents reported increasing pill counts per prescription. Fewer respondents in the African region reported improvements in clinic visits deferrals between the month of highest COVID-19 impact and the current month at only 45% (10/22) compared with 79% (11/14) in the European Region and 65% (34/52) in the region of the Americas. Respondents in the Americas also experienced the highest level of deferrals earlier on (Fig. 3) . Conversely, An Official Learning Resource of AASLD Impact of COVID-19 Response on Hepatitis Care Laury, Hiebert, and Ward review fewer respondents in African countries reported deferrals in laboratory testing and imaging compared with the Americas and Europe (Table 1 , mitigation strategies for distance-based care). These differences were found to be significant when comparing the Americas with the African Region at the 95% confidence level (P = 0.029 and P = 0.001), but not between the European Region and the African Region.

The results of this survey reveal challenges and opportunities for hepatitis care introduced by the response to the COVID-19 pandemic. The emergence of COVID-19 resulted in an immediate decrease in patients receiving HBV and HCV testing and treatment. Others have reported similar declines. [3] [4] [5] [6] Although most respondents to our survey reported improvements in the number of patients receiving these services, ongoing monitoring can assess whether these improvements are sustained particularly during surges of COVID-19 in communities.

Fortunately, the survey results suggest that many clinicians and program managers implemented recommended mitigation strategies to protect patients and providers from SARS-CoV-2 infection. Also, the response to the COVID-19 pandemic has created new opportunities to strengthen hepatitis elimination efforts. For example, the strengthening of the telemedicine infrastructure, as well as expansion of diagnostic capacity can innovate hepatitis care, expanding access to hepatitis testing and treatment. 7, 8 The varied use of mitigation strategies across regions reveals the value of sharing lessons learned to translate these innovative strategies into simpler models of routine hepatitis care.

The survey has limitations. Although respondents were from 44 countries, the survey is limited by responses coming from relatively small convenience sample of clinicians and program managers. The survey was translated into only French and Spanish, which may have limited participation.

In summary, the COVID-19 pandemic resulted in decreases in hepatitis prevention, testing and treatment, slowing or halting, in the immediate term, progress toward goals for hepatitis elimination. However, mitigation strategies to stop transmission helped clinicians safely overcome these declines in hepatitis care during the pandemic response and hold promise for sustaining these strategies to simplify hepatitis testing and treatment particularly as cases of COVID-19 wane. The hepatitis community can disseminate lessons learned for safely continuing service delivery, assist programs in introducing mitigation strategies, and capitalize on these opportunities for innovative changes in clinical care that advance progress toward hepatitis elimination. 

For Global Hepatitis Elimination, Task Force for Global Health

Geneva: World Health Organization

Synthesis of liver associations recommendations for hepatology and liver transplant care during the COVID-19 pandemic

Effect of the COVID-19 pandemic on viral hepatitis services in sub-Saharan Africa

The impact of COVID-19 on hepatitis elimination

Impact of COVID-19 on global HCV elimination efforts

An epidemic in the midst of a pandemic: opioid use disorder and COVID-19

Telemedicine in liver disease and beyond: can the COVID-19 crisis lead to action?

COVID-19 and liver diseases: revamping remote care initiatives in hepatology